Drug maker GSK is buying a biotechnology company developing vaccines for respiratory and infectious diseases that generate multiple immune responses. . . . → Read More: GSK Acquires Advanced Vaccine Biotech in $3.3B Deal
|
|||||
       
 |
 Comments are closed  Finance, New products  biomedical, biotechnology, chemistry, equity, investment, life sciences, merger, pharmaceuticals, physical sciences, U.K. 
A collaboration between developers of protein analytics and test-strip diagnostics aims to create a quicker, more sensitive, easy-to-use Covid-19 detection test. . . . → Read More: Partnership Developing Faster, Sensitive Covid-19 Test Comments are closed Joint ventures/collaborations, New products biomedical, biotechnology, cancer, chemistry, Covid-19, engineering, life sciences, medical device, merger, physical sciences, U.K. 
A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC. . . . → Read More: Digital Mental Therapy Company to Go Public in Merger Comments are closed Finance, New products biomedical, computer science, engineering, equity, investment, IPO, life sciences, mathematics, medical device, merger, physical sciences, software 
Global drug maker Novo Nordisk is acquiring biotechnology company Dicerna Pharmaceuticals Inc. in an all-cash deal valued at $3.3 billion. . . . → Read More: Novo Nordisk Buys RNA Biotech in $3.3B Deal Comments are closed Finance biomedical, biotechnology, equity, Europe, genomics, investment, life sciences, merger, pharmaceuticals 
A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger Comments are closed Finance biomedical, biotechnology, clinical trials, entrepreneurs, equity, Europe, investment, IPO, merger, pharmaceuticals 
A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition. . . . → Read More: RNA Manufacturer Goes Public in $282M Merger Comments are closed Finance agriculture, biomedical, biotechnology, chemistry, Covid-19, entrepreneurs, equity, investment, IPO, life sciences, manufacturing, merger, physical sciences 
Drug maker Bayer is acquiring a company discovering new therapies with a technology that reveals complex protein targets considered difficult to address. . . . → Read More: Protein Chemistry Biotech Acquired in $2B Deal One comment - (Comments are closed) Finance biomedical, biotechnology, chemistry, entrepreneurs, Europe, investment, life sciences, merger, pharmaceuticals, physical sciences, preclinical
Drug maker Sanofi is purchasing biotechnology company Translate Bio, a developer of messenger RNA vaccines and therapies, and a long-time collaborator. . . . → Read More: Sanofi Acquires mRNA Developer in $3.2B Deal One comment - (Comments are closed) Finance, Joint ventures/collaborations biomedical, biotechnology, clinical trials, Covid-19, equity, Europe, genomics, investment, life sciences, merger, pharmaceuticals 
A new enterprise discovering treatments for neurodegenerative diseases is merging with another start-up and raising $73 million its first venture round. . . . → Read More: Neuro Disease Start-Up Raises $73M in Early Funds One comment - (Comments are closed) Finance, New products biomedical, biotechnology, entrepreneurs, equity, Europe, genomics, investment, life sciences, merger, pharmaceuticals, university, venture capital 
A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition. . . . → Read More: Synthetic Bio Company Goes Public in $2.5B Merger Comments are closed Finance biotechnology, economics, engineering, entrepreneurs, equity, genomics, investment, IPO, life sciences, merger, pharmaceuticals |
|
|||
|
Copyright © 2022 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
